Page last updated: 2024-09-03

tazobactam and Diabetic Foot

tazobactam has been researched along with Diabetic Foot in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (20.00)18.2507
2000's2 (40.00)29.6817
2010's1 (20.00)24.3611
2020's1 (20.00)2.80

Authors

AuthorsStudies
Sivashanmugam, K; Srivastava, P1
Alder, J; Arvis, P; Dryden, M; Gyssens, IC; Kujath, P; Nathwani, D; Reimnitz, P; Schaper, NC1
Dittrich, P; Hoffmann, C; Kerl, H; Krause, R; Legat, FJ; Salmhofer, W; Scholz, S; Tscherpel, J; Tscherpel, T; Zenahlik, P1
Choudhri, S; Giordano, P; Lipsky, BA; Song, J1
Diepersloot, RJ; Hoekstra, JB; Hoynck van Papendrecht, AA; van Kraaij, MG; Veldkamp, KE; Zeillemaker, AM1

Trials

2 trial(s) available for tazobactam and Diabetic Foot

ArticleYear
Efficacy and safety of IV/PO moxifloxacin and IV piperacillin/tazobactam followed by PO amoxicillin/clavulanic acid in the treatment of diabetic foot infections: results of the RELIEF study.
    Infection, 2013, Volume: 41, Issue:1

    Topics: Administration, Intravenous; Administration, Oral; Aged; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Aza Compounds; Bacteria; Bacterial Infections; Diabetic Foot; Female; Fluoroquinolones; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Penicillanic Acid; Piperacillin; Quinolines; Tazobactam; Treatment Outcome

2013
Treating diabetic foot infections with sequential intravenous to oral moxifloxacin compared with piperacillin-tazobactam/amoxicillin-clavulanate.
    The Journal of antimicrobial chemotherapy, 2007, Volume: 60, Issue:2

    Topics: Aged; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Aza Compounds; Bacterial Infections; Databases, Factual; Diabetic Foot; Double-Blind Method; Female; Fluoroquinolones; Humans; Male; Moxifloxacin; Penicillanic Acid; Piperacillin; Quinolines; Tazobactam

2007

Other Studies

3 other study(ies) available for tazobactam and Diabetic Foot

ArticleYear
Efficacy of sub-MIC level of meropenem and ciprofloxacin against extensive drug-resistant (XDR) Pseudomonas aeruginosa isolates of diabetic foot ulcer patients.
    Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases, 2021, Volume: 92

    Topics: Anti-Bacterial Agents; Cephalosporins; Ciprofloxacin; Diabetic Foot; Drug Resistance; Humans; Meropenem; Microbial Sensitivity Tests; Piperacillin; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam

2021
Penetration of piperacillin and tazobactam into inflamed soft tissue of patients with diabetic foot infection.
    Antimicrobial agents and chemotherapy, 2005, Volume: 49, Issue:10

    Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Area Under Curve; Diabetic Foot; Extracellular Fluid; Female; Humans; Inflammation; Male; Microdialysis; Middle Aged; Penicillanic Acid; Piperacillin; Soft Tissue Infections; Tazobactam

2005
Piperacillin/tazobactam therapy for diabetic foot infection.
    Foot & ankle international, 1998, Volume: 19, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Diabetic Foot; Drug Combinations; Enzyme Inhibitors; Female; Humans; Male; Middle Aged; Penicillanic Acid; Penicillins; Piperacillin; Staphylococcal Infections; Tazobactam

1998